Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer - Summary - MDSpire

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

  • By

  • Agata Świętek

  • Joanna K. Strzelczyk

  • Dorota Hudy

  • Zenon P. Czuba

  • Karolina Snopek-Miśta

  • Mariusz Kryj

  • Katarzyna Kuśnierz

  • Marcin Zeman

  • Malgorzata Oczko-Wojciechowska

  • Daria Handkiewicz-Junak

  • Janusz Strzelczyk

  • July 2, 2026

  • 0 min

Share

Objective:

To assess IL-6, IL-8, IL-11, and leptin concentrations in tumor and corresponding surgical margins and determine their relationship with clinical and demographic variables.

Approach:
  • Study Design: A multiplex immunoassay and ELISA were used to quantify cytokine levels in tissue homogenates from 59 patients with GEP-NETs.
Key Findings:
  • Higher concentrations of IL-6, IL-8, IL-11, and leptin were found in tumor samples compared to surgical margins.
  • IL-6 and leptin levels were significantly elevated in tumors and margins from patients with T4 stage.
  • Tumor leptin levels were increased in patients with N2 compared to N0.
  • Margin IL-11 concentration was higher in N0 compared to N2.
  • Tumor IL-6 and leptin levels were significantly higher in patients with M1 compared to M0.
  • Cytokine levels varied according to tumor localization.
Interpretation:

The study demonstrated altered expression of IL-6, IL-8, IL-11, and leptin in GEP-NET tissues.

Limitations:
  • The study included a limited sample size of 59 patients.
  • Cytokine profiles were not fully characterized in all tumor types.
Conclusion:

The findings highlight the relevance of inflammatory and metabolic signaling within the GEP-NET microenvironment.

Original Source(s)

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

  • by Agata Świętek, Joanna K. Strzelczyk, Dorota Hudy, Zenon P. Czuba, Karolina Snopek-Miśta, Mariusz Kryj, Katarzyna Kuśnierz, Marcin Zeman, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Janusz Strzelczyk

  • July 2, 2026

Related Content

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target

Molecular changes during AT/RT progression associated with epithelial–mesenchymal transition and extracellular matrix changes

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer